Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

In this double-blind trial, patients with stage 1 to 4 chronic kidney disease and type 2 diabetes were randomly assigned to receive finerenone or placebo. Finerenone treatment was superior with regard to the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarctio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-12, Vol.385 (24), p.2252-2263
Hauptverfasser:	Pitt, Bertram, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Ruilope, Luis M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Aged Albumin Albuminuria - etiology Angiotensin Cardiology Cardiology General Cardiovascular Diseases - epidemiology Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cerebral infarction Chronic Kidney Disease Clinical medicine Congestive heart failure Creatinine Design Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Double-Blind Method Endocrinology Epidermal growth factor receptors Female Glomerular filtration rate Heart failure Hospitalization Humans Hyperkalemia Kidney diseases Male Middle Aged Mineralocorticoid Receptor Antagonists - adverse effects Mineralocorticoid Receptor Antagonists - therapeutic use Myocardial infarction Naphthyridines - adverse effects Naphthyridines - therapeutic use Nephrology Patient safety Placebos Potassium Proportional Hazards Models Renal failure Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Renin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this double-blind trial, patients with stage 1 to 4 chronic kidney disease and type 2 diabetes were randomly assigned to receive finerenone or placebo. Finerenone treatment was superior with regard to the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2110956